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Abstract 
Background Intraabdominal fibromatosis often involves the mesentery root which is 
nonresectable by conventional surgery. Multivisceral transplant (MVT), as a potential 
cure to nonresectable fibromatosis, has rarely been reported and the prognosis is 
unknown. Methods Six patients who underwent MVT for intraabdominal fibromatosis 
were reviewed. Clinicopathological features, immunohistochemistry for β-catenin, 
p53, and Ki67, and outcomes were evaluated. Appropriate data for comparative 
analysis were obtained from a cohort of 24 patients who underwent conventional 
resection for intraabdominal fibromatosis. Results Among 6 MVT patients, 4 had 
familial adenomatous polyposis (FAP). Two patients had an initial intestinal 
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transplantation, three had multiple prior surgeries and two had adjuvant therapy. One 
patient died of hemorrhagic stroke shortly after MVT, and 5 patients (83%) survived 
with a median followup of 64 months. The 1-year and 5-year survival rates were 67% 
for all 5 patients. Two patients had recurrences after MVT and one of them had FAP. 
In comparison, 6 out of 24 patients who underwent conventional surgery had FAP; 6 
(25%) had recurrences and 3 had FAP. For FAP patients, the mean recurrence time 
was 13 months for MVT versus 6 months for conventional surgery. Ki67 proliferative 
index, β-catenin, and p53 expression did not significantly correlate to recurrence. 
Conclusions MVT is a viable option for patients who have nonresectable 
intraabdominal fibromatosis with promising surviving rates, although recurrence still 
occurs. Surgical margin, Ki67 proliferative index, β-catenin, and p53 expression are 
not predicative for recurrence of fibromatosis. 
 
INTRODUCTION 
Fibromatosis, first described by Stout et al., is a well-differentiated fibroblastic tumor. 
Morphologically, the tumor cells display features of infiltrating growth pattern, 
abundant collagen, low mitotic activity, local aggressiveness, and lack of malignant 
histology or potential for distant metastasis.1 The tumor cells are positive for smooth 
muscle actin, desmin, calponin, and estrogen receptor-β, and negative for CD34.2 At 
molecular levels, sporadic fibromatosis harbors mutations of gene CTNNB1, which 
encodes β-catenin protein. Therefore, the presence of nuclear expression of β-
catenin is frequently used as a diagnostic tool.3,4 
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Based on locations, fibromatosis is further classified into two main types, 
superficial and deep. The former tends to involve superficial fascia or aponeurosis, 
and the deep type is categorized as extraabdominal (60%), abdominal wall (25%), 
and intraabdominal (desmoid tumor, 15%).5 Multidisciplinary treatment, including 
surgery, radiation and adjuvant therapy, has been applied. Among them, surgery is 
the essential approach, although limitation exists6. First, intraabdominal fibromatosis, 
especially in patients with familial adenomatous polyposis (FAP), often involves the 
bowel or mesentery root, which is nonresectable by traditional surgery.7 Secondly, 
wide resection with a negative surgical margin cannot always be achieved, which 
yields a high rate of recurrence.7 Thirdly, repeated surgeries inevitably lead to 
formidable short gut syndrome that significantly impairs quality of life. All these post 
a challenge to conventional surgery. 
Multivisceral transplant (MVT), as the last straw, is a potential treatment for 
patients with nonresectable fibromatosis that is beyond conventional surgery. Rare 
MVT cases have been reported, although the prognosis and predicators are largely 
unknown.8-13 This report aimed to study the survival and recurrence in a series of 6 
patients who had conventionally nonresectable fibromatosis and underwent MVT.  
 
MATERIALS AND METHODS 
Patients 
Six patients who underwent MVT for nonresectable intraabdominal fibromatosis were 
identified in the Indiana University Health surgical pathology database from 2005 to 
2015. The study was approved by the Institutional Review Board. Organ 
procurement, preservation, and the procedure of MVT were followed as previously 
described.14,15 The evisceration consisted of dissection of the intraabdominal organs 
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including celiac and superior mesenteric artery inflow, liver, pancreaticoduodenal 
complex, small bowel, and part of colon. Lymph nodes in the retroperitoneum were 
also resected during the procedure. The cluster graft organs included stomach, small 
bowel, and portion of colon, liver, and pancreas. All patients received antibody-based 
induction immunosuppression with calcineurin-inhibitor–based maintenance and low 
dose steroids, as well as protocols of graft surveillance and infectious 
prophylaxis.16,17  
In comparison, 24 patients who underwent conventional surgeries for 
intraabdominal fibromatosis were identified from the same time period. Patients who 
had abdominal wall and parietal fibromatosis were excluded from the study. 
 
Histomorphologic review  
The cases were reviewed by two pathologists (ZC and JL) to compare the 
histomorphologic features. Tumor site, size and number, surgical margin status, 
involved organs, tumor necrosis, and mitosis were evaluated. Mitosis was assessed 
at a magnification of ×400 using an Olympus BX51 microscope. Representative 
fields were selected and at least 500 nucleated tumor cells were assessed for each 
case.  
 
Immunohistochemical evaluation 
Immunohistochemistry for assessing Ki67, p53, and β-catenin was performed on the 
tumor tissue of all MVT cases. A representative formalin-fixed, paraffin-embedded 
tumor section was used. Briefly, deparaffinized tissue sections were stained with 
antibodies against Ki67, p53, or β-catenin. Immunohistochemical staining was 
carried out with a mouse monoclonal anti-Ki67 (dilution 1:1; DAKO, Carpinteria, CA), 
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p53 (dilution 1:1, ONCOGENE SCIENCE, Cambridge, MA), and β-catenin (dilution 
1:1, ZYMED, South San Francisco, CA). A high pH buffer solution in a “PT module” 
was used for antigen retrieval followed by incubation times of 10 minutes each with 
primary antibody, Envision FLEX+M linker, Envision FLEX/horseradish peroxidase 
(Dako, Carpinteria CA), and diaminobenzidine.. 
Expression of Ki67 proliferation index and p53 was calculated by manual 
counting of camera-captured/printed image18 of at least 50 HPFs and/or 2000 
nucleated tumor cells (40X objective) in the area of expression and reported as a 
number of positive cells per 10 HPFs using an Olympus BX51 microscope.  
 
Statistics 
Categorical data were compared using the χ2 test. Continuous data were compared 
using Student t test. A P value less than 0.05 is considered statistically significant. 
 
RESULTS 
Demographics  
Three patients who received MVT were men (50%) and the average age of MVT 
group was 41 years (range, 29–60 years). Eleven patients who received 
conventional surgery were men (46%) and the average age was 42 years (range, 
15–70 years). There was no age or gender difference in two study groups (P > 0.05). 
 Four patients in MVT group and 6 patients in conventional group had FAP. 
Two FAP patients in MVT group had an initial intestine-only transplantation before 
MVT, and the allografts failed. Three patients in MVT group had prior multiple small 
bowel resections or subtotal colectomy. These patients in MVT group presented with 
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short gut syndrome or frozen abdomen (Table 2). Two MVT patients (#1 and 4) had 
received adjuvant therapy (tamoxifen, methotrexate, or imatinib, Table 2). 
 
Histopathologic evaluation 
As shown in Table 1, the primary site was mesentery for all patients in the study. The 
average size of tumor was 14.6 cm (range, 4.5–25 cm) in MVT group compared to 
that of 8.5 cm (range, 1.5–26 cm) in conventional group (P=0.19). The average 
number of tumor in MVT group was 3 (range, 1–9) that was statistically higher than 
that of 1.4 (range, 1–4) in conventional group (P=0.0005). Three patients in MVT 
group had positive resection margins (50%) compared to that of 54% in conventional 
group. Involved organs in MVT group included small bowel (100%), stomach (33%), 
pancreas (33%), spleen (33%), and liver (16%) which were more extensive in 
contrast to those of small bowel (100%), stomach (4%), and colon (12%) in 
conventional group. Necrosis was not present and mitotic figures were rare in both 
study groups.  The clinicopathological features of each individual patient who 
had MVT were shown in Table 2.  
 
Prognosis  
As shown in Table 3, among 6 MVT patients, 1 died of hemorrhagic stroke shortly 
after MVT and all patients in conventional group survived the procedure. For the 5 
patients who survived MVT, median followup time was 64 months (range, 4–116 
months) compared with 49 months (range, 1–106 months) in conventional group. 
One patient died 4 months post-MVT due to sepsis, and 1 patient in conventional 
group passed away after 6 months due to gastrointestinal tract bleeding. The overall 
1-year and 5-year survival rates were both 67% in MVT group compared to those of 
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96% in the conventional group. In MVT group, 2 patients (40%) had recurrences with 
a median recurrence time of 9 months (range, 4–13 months) in contrast to 6 patients 
(25%) in the conventional group with a median recurrence time of 23 months (range, 
5–74 months).  
One FAP patient passed away 4 months post-MVT due to sepsis in contrast 
to none in conventional group. The 1-year and 5-year survival rates for FAP patients 
in MVT group were 75% compared with 100% in conventional group. One FAP 
patient (25%) in MVT group had recurrence 13 months post-MVT and 3 (50%) FAP 
patients in control group had recurrences with a median time of 6 months (5, 6 and 
33 months). The single non-FAP patient in MVT group had a recurrence time at 4 
months after MVT. Among 18 non-FAP patients in conventional group, 3 (17%) had 
recurrence with a median time of 32 months (14, 32 and74 months)).  
Further analysis was performed in 5 MVT patients respective to recurrence. 
As shown in Table 4, recurrence occurred in 2 of 3 patients whose surgical margins 
were positive. Although there was likely a trend that positive margin was associated 
with recurrence, it was not statistically significant (P > 0.05). 
 
Immunohistochemistry study  
Immunohistochemistry for Ki67, p53, and β-catenin was performed on the tumor 
tissue in MVT group (Figure 1; Table 4). In the 2 patients with recurrent disease, 
83% (mean; range, 82–84%) of tumor cells were positive for nuclear β-catenin 
immunostaining compared to 51% (mean; range, 31–64%) in 3 nonrecurrent cases 
(P>0.05). Ki67 proliferation indexes were 4% (mean; range, 3–5%) in recurrent 
cases compared with 2% (mean; range, 0–3%) in nonrecurrent group (P>0.05). p53 
immunoreactivity was 5% (mean; range, 2–8%) versus 4% (mean; range, 0–8%) 
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between recurrences and nonrecurrences with no statistical significance (P>0.05). 
Although the expression levels of Ki67, p53, and β-catenin in recurrent tumors 
appeared higher than those of the nonrecurrence, there was no statistical 
significance. 
 
DISCUSSION 
MVT was first performed 30 years ago by Dr. Starzl et al. in a child with short gut 
syndrome and secondary liver failure.19 Since then, MVT has been performed 
around the world with varying degrees of success. Major indications for MVT in both 
children and adults include gastroschisis, necrotizing enterocolitis, intestinal atresia, 
mesenteric thrombosis, trauma, and intestinal dysmotility syndrome.20 Recently, 
nonresectable intraabdominal fibromatosis involving the mesenteric root has been 
indicated for MVT. However, given the complex natures of MVT and associated high 
risks, only a handful studies have been published (Table 5).8-13 The first MVT for 
intraabdominal fibromatosis was reported by Misiakos et al. in 1999.8 The patient 
had Gardner syndrome and fibromatosis with multiple episodes of intestine 
resections and eventually developed short gut syndrome. Additionally, prolonged 
total parenteral nutrition impaired the liver. After MVT, fibromatosis recurred in this 
patient in thoracic wall twice that was successfully resected. In 2001, Chatzipetrou et 
al. reported two MVT cases, in which only one patient survived the procedure without 
recurrence.9 In 2002 and 2005, Jovine et al. and Tryphonopoulos et al. published 3 
and 2 cases, respectively, with a total of 4 surviving patients, although the status of 
recurrences was not provided.10,11 In Tryphonopoulos’ study, 3 patients had intestinal 
autotransplantation and all survived the procedure without recurrence of the 
disease.11 In 2011, Cruz et al. reported 10 liver-sparing modified MVT.12 All patients 
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had FAP and short gut syndrome with extensive fibromatosis involving the pancreas 
and duodenum. All patients survived the procedure without recurrence. The overall 
cumulative survival rate was 90% at 1 year and 77% at 10 years. In 2013, 
Nikeghbalian et al. published one case. The patient survived the procedure without 
recurrence.13 In the current report, 6 patients received MVT for nonresectable 
fibromatosis with a median followup of 64 months. To our knowledge, this represents 
the second largest series in the literature.  
The overall 1-year and 5-year survival rates were both 67% for MVT patients; 
and the recurrence rate was 40% for the 5 followed-up patients. In summary, 22 
(88%) out of 25 patients who survived MVT have been reported so far in the English 
literature. Among them, 3 (15%) had known recurrence. In comparison, the overall 1-
year and 5-year survival rates were both 96% for the conventional surgery group, 
and the recurrence rate was 25% for the followed-up patient. These results are 
comparable with the 1- and 5-year recurrence-free survival rates of 81.3% and 52.8 
% reported in Johns Hopkins study.21 
The 6 patients in MVT group had multiple tumors and the tumor load was 
larger extensively involving multiple visceral organs in comparison to those in 
conventional group.  Among 6 MVT patients, most had prior surgeries including 
multiple small bowel resection (1), subtotal colectomy (2), and isolated small 
intestinal transplantation (2). Among them, two patients had adjuvant therapy. But all 
these treatments failed to control the tumor progression which fatally involved the 
mesentery root and multiple visceral organs. As noted, the largest size of the tumor 
in one of our patient (#3) was less than 5 cm, but this patient had 4 fibromatosis 
tumors (4.5 cm, 4 cm, 3.5 cm and 2.5 cm) involving multiple visceral organs (liver, 
stomach, pancreas, small bowel and spleen) that caused short gut syndrome. 
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Although autologous reconstruction of superior mesentery artery base, auto-
transplantation or ex vivo resection would be feasible for some small-size tumors, 
they were not suitable in this particular case, because of the extensive tumor 
involvement in multiple important visceral organs that made it nonresectable by 
conventional surgery.  It is worth mentioning that MVT is truly the last straw that 
should be considered for fibromatosis patient when all the other possible options are 
excluded, given the complex nature and the high risk of the procedure.  
An interesting finding of our study is that FAP patients in MVT group had a 
trend of lower recurrence rate compared to their counterparts in conventional 
surgery, which keeps in line with Cruz’s observation.12 Although sporadic and FAP-
associated fibromatosis both have enhanced β-catenin protein expression, the 
mechanisms are different. It is known that the characteristic APC mutation in FAP 
causes nuclear accumulation of β-catenin protein, while the CTNNB1 mutation leads 
to nuclear accumulation of β-catenin protein in sporadic fibromatosis.22 This 
difference in pathogenesis might play a role in recurrence, although further 
investigation is warranted.  
Prognostic factors for recurrence in MVT were also studied. Our data indicate 
that surgical margin, Ki67 proliferative index, β-catenin, and p53 expression do not 
significantly correlate to recurrence. Given the small size of cases, more studies from 
multiple transplant centers are warranted to finalize the conclusion. 
In summary, MVT is a viable option for patients with advanced intraabdominal 
fibromatosis who are, otherwise, ultimately fatal and not amenable to conventional 
options. Surgical margin, Ki67 proliferative index, β-catenin, and p53 expression are 
not predicative for recurrence of fibromatosis in patients who takes MVT. 
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Table 1. Clinical and histopathologic comparison of intraabdominal fibromatosis in 
patients with multivisceral transplant (MVT) or conventional surgery. 
 MVT 
(n=6) 
Conventional surgery 
(n=24) 
Primary site Mesentery Mesentery 
Mean size (range) 14.6 cm (4.5–25) 8.5 cm (1.5–26) 
Average number of tumor (range) 3 (1–9) 1*(1–4) 
Margin positivity 3 (50%)  13 (54%)  
Organs involved Small bowel (100%) 
Stomach (33%) 
Pancreas (33%) 
Spleen (33%) 
Liver (16%) 
Small bowel (92%) 
Stomach (4%) 
Colon (12%) 
Necrosis  Not present Not present 
Mitosis Rare Rare 
*P =0.0005 compared to the MVT group.   
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Table 2. The clinicopathological characteristics of the 6 patients who had 
multivisceral transplant for intraabdominal fibromatosis. 
Patient 1 2 3 4 5 6 
Age/Sex 33/M 60/F 29/M 33/F 50/F 39/M 
Number of tumor 1 3 4 9 3 1 
Size of tumor (the 
largest) 15 cm 15 cm 4.5 cm 16 cm 25 cm 12 cm 
FAP status Yes Yes Yes No No Yes 
Organ involvement Small bowel Small bowel 
Liver, 
stomach, 
pancreas, 
small bowel, 
spleen 
Stomach, 
Small bowel, 
pancreas, 
abdominal 
wall, 
Small bowel, 
spleen Small bowel 
On TPN No No Yes No Yes Yes 
Liver failure No No No No No No 
Organs transplanted 
Stomach, 
small bowel, 
portion of 
colon, liver, 
and pancreas 
Stomach, 
small bowel, 
portion of 
colon, and 
pancreas 
Stomach, 
small bowel, 
portion of 
colon, liver, 
and 
pancreas 
Stomach, 
small bowel, 
portion of 
colon, and 
pancreas 
Stomach, small 
bowel, portion 
of colon, liver, 
and pancreas 
Stomach, small 
bowel, portion 
of colon, liver, 
and pancreas 
Necrosis Not present Not present Not present Not present Not present Not present 
Ki67 0.0% 5.7% 5.7% 2.8% 3.1% 0.6% 
MVT complication 
(infection, shock) No No No No 
Died of peri-
operative 
hemorrhagic 
stroke 
Died of sepsis 
4 m later 
Pre-MVT condition 
and pre-MVT surgery 
Subtotal 
colectomy, 
Short gut 
syndrome 
Frozen 
abdomen 
Multiple 
small bowel 
resections,  
short gut 
syndrome 
Omental and 
subtotal 
colectomy; 
short gut 
syndrome 
Initially pre-
MVT intestinal 
transplantation 
and allograft 
failure 
Initially pre-
MVT intestinal 
transplantation 
and allograft 
failure 
Adjuvant therapy 
(chemo or tamoxifen) 
Yes(Tamoxifen 
and 
methotrexate) No No 
Yes (Imatinib 
and 
tamoxifen) No No 
Follow up time 116  64 5 78 0 4 
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(months) 
Recurrence and time 
elapsed (months) No No Yes (4) Yes (13) n/a No 
Prognosis 
(dead/alive) Alive Alive Alive Alive Dead Dead 
 
Abbreviation: FAP, familial adenomatous polyposis; MVT, multivisceral transplant; 
TPN, total parenteral nutrition. 
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Table 3. Followup and recurrence of intraabdominal fibromatosis.  
 
 
Total FAP Non-FAP 
MVT* Conventional MVT Conventional MVT Conventional 
Number 5 24 4 6 1 18 
Followup time (months; range)  64 (4–116) 49 (1–106) 71 (4–116)  46 (6–106) 5 (5) 49 (1–98) 
Recurrence  2 (40%) 6 (25%) 1 (25%)  3 (50%) 1 (100%) 3 (17%) 
Medium recurrence time 
(months; range) 9 (4–13) 23 (5–74) 13 (13) 6 (5–32) 4 (4) 32 (14–74) 
 
*One patient died shortly after MVT due to hemorrhagic stroke. 
Abbreviation: FAP, familial adenomatous polyposis; MVT, multivisceral transplant  
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Table 4. Recurrence of intraabdominal fibromatosis in multivisceral transplant (MVT) 
patients 
 
MVT Recurrent Nonrecurrent 
Number of patients* 2 3 
Followup period (months; range) 42 (5–78) 64 (4–116) 
Recurrence time (months; range) 9 (4–13) N/A 
β-catenin-nuclear positive immunoreactivity (range) 83% (82–84%) 58% (31–64%) 
Ki67-positive immunoreactivity (range) 4% (3–5%) 1% (0–3%) 
p53-positive immunoreactivity (range) 5% (2–8%) 3% (0–8%) 
Positive surgical margin  2 (100%) 1 (33%) 
 
*One patient died shortly after MVT due to hemorrhagic stroke and this case is 
excluded from the analysis of recurrence. 
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Table 5. Published series of multivisceral transplant to treat nonresectable intraabdominal fibromatosis 
 
Reports Year Case 
number 
Survived 
MVT 
Recurrence Followup time 
(median months) 
Misiakos8 1999 1 1  1 N/A 
Chatzipetrou9 2001 2 1 0 43 (range 38–48) 
Jovine10 2002 2 2  N/A 6 (range 5–6) 
Tryphonopoulos11 2005 3 2 N/A 63 (range 13–108) 
Cruz12 2011 10 10 0 50 (range, 18–128) 
Nikeghbalian13 2013 1 1 0 31 
Chi (current) 2017 6 5  2 64 (range, 4–116) 
Summary N/A 25 22 (88%) 3 (15%) 4–128 
 
Abbreviation: MVT, multivisceral transplant; N/A, not applicable.  
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Figure Legend 
Figure 1. Intraabdominal fibromatosis. (A) High-power view of fibromatosis showing 
cytologically bland spindle- or stellate-shaped fibroblastic cells arranged into 
intersecting fascicles with collagenous deposition (H&E, magnification x200). (B) 
Immunohistochemically, fibroblastic cells are strongly positive for β-catenin in a 
nuclear staining pattern (magnification x200). Immunostaining for Ki67 proliferative 
index (C) and p53 (D) highlights rare spindle cells (magnification ×200). 
 
 
 
 
 
